Novartis Backing Revamped Desenex Antifungals With $7.5 Mil.
This article was originally published in The Tan Sheet
Executive Summary
Novartis Consumer Health is streamlining and repackaging its Desenex athlete's foot care line to consist of only prescription-strength products; the firm is phasing out the regular strength items.
You may also be interested in...
Novartis Desenex Max Supported With Comparative TV Ads, FSIs
The "triple-strength" of Desenex Max compared to other available OTC athlete's foot remedies is emphasized in promotions accompanying the launch of Novartis' new terbinafine hydrochloride 1% cream.
Novartis Desenex Max Supported With Comparative TV Ads, FSIs
The "triple-strength" of Desenex Max compared to other available OTC athlete's foot remedies is emphasized in promotions accompanying the launch of Novartis' new terbinafine hydrochloride 1% cream.
Novartis Desenex Max Supported With Comparative TV Ads, FSIs
The "triple-strength" of Desenex Max compared to other available OTC athlete's foot remedies is emphasized in promotions accompanying the launch of Novartis' new terbinafine hydrochloride 1% cream.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: